Artery Widening or Stenting After Clot Removal in Stroke From Narrowed Brain Arteries
Compares adding artery widening or stenting after clot removal in adults with stroke.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Bailout Intracranial Angioplasty or Stenting After Thrombectomy for Acute Intracranial Atherosclerotic Large Vessel Occlusion (ANGEL-REBOOT 2)
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an acute stroke caused by a blocked large brain artery, likely due to narrowing from atherosclerosis, who have had a thrombectomy (clot removal procedure).
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Acute ischemic stroke with a large vessel blocked (internal carotid, middle cerebral M1, vertebral V4 or basilar artery), NIHSS score of 6 or more, 24 hours or less from symptom onset to puncture, and a pre-stroke mRS of 0-2. Part 1: artery reopened (eTICI 2b or better) with 70% or more narrowing left. Part 2: artery not reopened after at least two thrombectomy attempts.
- Earlier treatment
- Must have had thrombectomy: 1-2 attempts for Part 1, at least two attempts for Part 2.
- Biomarker or test result
- Scan scores: ASPECTS of 6 or more (anterior stroke); pc-ASPECTS of 6 or more and Pons-Midbrain Index below 3 (posterior stroke).
Main reasons for not taking part
- Bleeding in the brain on the first scan
- Heart-related clot source, such as atrial fibrillation
- Cannot take antiplatelet medicine
- Pregnant or breastfeeding
- Life expectancy under 1 year
Read by machine on 9 November 2026.
Where in China
- Beijing Tiantan Hospital,Capital Medical UniversityBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Feng Gao
- Trial code
- NCT07618052
- Record updated
- 1 June 2026
- Original description
A multicenter, randomized, open-label, blinded-endpoint trial with a concurrent prospective observational cohort to compare bailout intracranial angioplasty or stenting versus standard therapy on functional outcome, stroke recurrence, and mortality in patients with acute intracranial atherosclerotic stenosis-related large vessel occlusion after thrombectomy.Read full original descriptionShow less
Efficacy and Safety of Bailout Intracranial Angioplasty or Stenting After Thrombectomy for Acute Intracranial Atherosclerotic Large Vessel Occlusion: A Clinical Trial Combining a Randomized Controlled Trial and a Concurrent Prospective Observational Cohort
A multicenter, randomized, open-label, blinded-endpoint trial with a concurrent prospective observational cohort to compare bailout intracranial angioplasty or stenting versus standard therapy on functional outcome, stroke recurrence, and mortality in patients with acute intracranial atherosclerotic stenosis-related large vessel occlusion after thrombectomy.
Inclusion: Age≥18 years; Time interval from symptom onset to puncture ≤24 hours; National Institute of Health Stroke Scale (NIHSS) Score ≥6 before randomisation; Pre-stroke modified Rankin Scale (mRS) of 0-2; Each patient or their legal representative must provide written informed consent before enrolment; Imaging Inclusion Criteria:; For patients with anterior circulation stroke, a CT or DWI-based Alberta Stroke Program Early CT Score (ASPECTS) of ≥6 is required; For patients with posterior circulation stroke, CT or DWI-based posterior circulation ASPECTS (pc-ASPECTS) of ≥6 and Pons-Midbrain Index (PMI) of <3 are required; Angiographic Inclusion Criteria:; Acute ischemic stroke (AIS) resulting from large vessel occlusion (LVO) involving the intracranial internal carotid artery, the M1 segment of the middle cerebral artery, the V4 segment of the vertebral artery, or the basilar artery, with high suspicion of intracranial atherosclerotic stenosis-related large-vessel occlusion (ICAS-LVO); Part 1 (RCT): Successful recanalization of the occluded artery (eTICI ≥ 2b) with residual stenosis ≥ 70% after 1-2 thrombectomy attempts; Part 2 (Prospective observational cohort): Failure to achieve successful recanalization (eTICI 0-2a) after at least two thrombectomy attempts. All other inclusion criteria are identical to those for Part 1; Occluded artery amenable to angioplasty (balloon dilation and/or stenting) by the judgement of the treating neurointerventionalist.
Exclusion: Concurrent participation in another drug or device trial, or expected participation within the following 3 months; Any sign of intracranial hemorrhage (ICH, except microbleeds) on baseline brain imaging; Any indication of intracranial vessel perforation during thrombectomy; Stenosis caused by non-atherosclerotic intracranial arteriopathies (e.g., autoimmune vasculitis, vasospasm, cerebral artery dissection); Evidence of cardioembolism (e.g., atrial fibrillation, prosthetic heart valve, infective endocarditis, mitral stenosis, atrial myxoma, intracardiac thrombus/vegetation, left ventricular aneurysm, etc.); History of contraindication to the use of contrast medium; Refractory hypertension (defined as systolic blood pressure>185 mmHg or diastolic blood pressure>110 mmHg) that cannot be controlled by drug treatment; Patients whose life expectancy is less than 1 year (such as patients with malignant tumor, advanced cardiopulmonary disease, etc.); Known dementia or psychiatric disorder that precludes completion of neurological assessments and follow-up; Any other condition deemed by the site investigator to make the patient unsuitable for participation; Known hereditary or acquired bleeding tendency, lack of coagulation factors, or oral anticoagulants with INR>1.5; Blood glucose<2.8 or>22.2 mmol/L; Platelet count<100*109/L, serum creatinine>2.0 g/L (177 μ mol/L), or glomerular filtration rate<30 ml/(min*1.73 m2); CT or MR imaging evidence of intracranial tumor (except small meningiomas or cerebral aneurysms < 3mm in diameter); Presence of tandem lesion in the extracranial segment of the internal carotid artery or vertebral artery, or intracranial arterial stenosis with distal vessel occlusion; Contraindication for antiplatelet treatment; Excessive vascular tortuosity or anatomical variants that may preclude successful delivery or positioning of interventional devices; Known pregnancy or lactation, or positive pregnancy test before randomization (or before enrollment).